- TRADE NAME: Yupelri (Theravance Biopharma)
- INDICATIONS: indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- CLASS: Anticholinergic
- HALF-LIFE: 22–70 hours
- FDA APPROVAL DATE: 11/09/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cyclosporine - PREGNANCY: No adequate studies conducted. Advised to contact physician if pregnancy occurs while taking drug.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
